Company / Cash per Share
Spyre Therapeutics, Inc. Cash per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$1.42
FY2025
5-year range
$0.32 / $72.26
FY2021-FY2025
Trend
-42.6%
vs FY2024
Sector context
#131 of 205
Health Care
What the data says
At $1.42, Spyre Therapeutics, Inc.'s cash per share ranks #131 of 205 in the Health Care sector. Cash per Share has fluctuated over the past 10 years, ranging from $0.32 in FY2021 to $72.26 in FY2023.
Based on SEC 10-K filings.
1.42 in FY2025 with a 5-year CAGR of -14.4%.
Declined from $72.26 to $1.42 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- +26.3%
- 5-Year CAGR
- -14.4%
- 10-Year CAGR
- -
Sector benchmark
#131 of 205 in Health CareTop 64% of 205This company $1.42 Sector average $72.93
▼
-98.0% below sector average
Key checks
Key Insights
- In FY2025, cash per share decreased 42.6% year-over-year.
- Ranks #131 out of 205 companies in the Health Care sector.
- Peak cash per share was recorded in FY2023.
- Lowest cash per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.42 | -42.6% |
| FY2024 | $2.48 | -96.6% |
| FY2023 | $72.26 | +10130.0% |
| FY2022 | $0.71 | +123.7% |
| FY2021 | $0.32 | -89.8% |
| FY2020 | $3.10 | +288.4% |
| FY2019 | $0.80 | -40.8% |
| FY2018 | $1.35 | +59.0% |
| FY2017 | $0.85 | -82.6% |
| FY2016 | $4.88 | -90.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026